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Magnitude of the problem
Cancer is a disease that mostly affects older individuals,
with approximately 60% of cancer morbidity and 70%
of cancer mortality occurring in patients over 65 years of
age.1,2 This age group is growing rapidly: in Australia in
2003, there were 3.35 million people aged 60 years and
over (17% of the population), compared to three million
people (16%) in 1998. It is expected these numbers will
increase steadily. In 2002, median life expectancy at age
65 years was 17.3 years for males and 20.8 years for
females. Since 1982, at 65 years of age males have
gained 3.7 years of life expectancy and females three
years. In 2003, just over half had a reported disability
(51%) and 19% had a profound or severe core-activity
limitation.3 People aged 85 years and over reported a
much higher need for assistance than those aged 60-69
years (84% compared with 26%).4
Ageing is an important part of human development and
it is influenced by the biological changes that occur, but
also reflects cultural and societal conventions. Specific
strategies to address these problems need to be
developed as a priority. Elderly cancer patients often
present with medical and physiologic problems that
make the selection of their optimal treatment
challenging. The problem is further confounded by
issues such as co-morbidity, poly-pharmacy, cognitive
impairments, emotional problems, functional limitations,
sensory impairment and a lack of social support. 
Until recently, almost all clinical cancer research under
represented elderly patients.5-8 Most of the published
trials in oncology have used chronological age limits to
define cancer patients as elderly; 65 or 70 and less often
80 years of age are commonly used limits for patients
with solid tumours. Data from these trials have been
extrapolated to guide treatment decisions in the elderly
population. Despite these limitations, physicians
attempt to tailor chemotherapeutic treatments for this
population of patients that limit exposure to potentially
futile or unjustifiably toxic treatments, while not denying
them beneficial treatments which may impact on
survival, symptoms and quality of life. This is further
complicated by the diversity and heterogeneity of this
population. At present, there are few evidence-based
guidelines or trials to assist in this regard.
Under-treatment of elderly cancer patients with dose
reduction of adjuvant chemotherapy or total therapeutic
abstention is not unusual in practice. Under-utilisation of
resources might also include access to palliative care,
treatment of pain, surgical reconstruction and
rehabilitation. Common justification for under-treatment
includes co-existing medical problems, chronological
age, lack or scarcity of data for that age group, lack of
relevant clinical trials and increased risk of adverse
events. 
In current practice, the elderly are often excluded from
participation in clinical trials and receive untested or
inadequate treatment based on unvalidated criteria.
Elderly specific clinical trials are an essential
requirement to guide clinicians more appropriately to
optimise chemotherapy delivery to this specific
population. Studies incorporating the pharmacodynamic
and the pharmacokinetic effects on ageing are
necessary. This paper will address issues related to
chemotherapy delivery in the elderly.
Impact on the pharmacokinetics and
pharmacodynamics
Ageing is associated with physiologic changes in
functional status, organ function and drug
pharmacokinetics. Physiologic reserve decreases
progressively with ageing.9-10 Organ specific age related
physiologic decline begins in the third decade of life. It
is not evident at times of rest but becomes most
apparent when the body is stressed.11 Both cancer and
its treatment can be considered as physiologic stressors
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and the age related decrease in physiologic reserve can
affect tolerance to cancer treatment. 
Ageing is associated with decreases in marrow reserve,
drug clearance and lean body mass. Furthermore,
concomitant co-morbidities that affect functional status,
general health and tumour symptoms are frequently
present in this patient population. Co-morbidities in older
patients can strongly affect the risk and behaviour of
cancer and their related treatment. This effect is
associated with syndromes with common patho-
physiologic mechanisms, such as diabetes mellitus, the
metabolic disorders and inflammatory diseases.12-15
The levels of a number of inflammatory cytokines have
been found to be elevated in common cognitive
disorders of ageing.16 The circulating level of Interleukin-
6 is elevated in most geriatric syndromes and often
reflects compromised muscular function.17 The
circulating level of C-reactive protein, another
inflammatory marker, predicts increased risk of
cardiovascular mortality.18 Non-specific markers of
autoimmunity, such as antinuclear antibodies, also tend
to increase with age.
A number of age related changes in drug absorption,
distribution, metabolism and excretion with ageing can
contribute to differences in treatment tolerance between
older and younger patients. An increased toxicity in
elderly patients with cancer may be due to increased
exposure to a drug either by prolonged half-life, due to
decreased elimination, or by impaired renal function and
also changes in pharmacodynamics caused by increased
vulnerability of organs with age. The volume of
distribution changes; total body water is reduced to
about 50% (instead of 60%), whereas total body fat
increases. Other factors associated with a change of
distribution are binding of drugs to erythrocytes (eg.
anthracyclines, epipodophyllotoxins and oxaliplatin) and
proteins (especially albumin). Thus, hypoproteinemia and
anaemia can alter drug distribution. The absorption of
drugs can be affected by decreased gastrointestinal
motility, decreased splanchnic blood flow, decreased
secretion of digestive enzymes and mucosal atrophy.19-20
However, to date no unfavourable data for orally applied
cytotoxic drugs due to a decreased absorption have been
reported in elderly patients.
With the increased use of oral therapy, drug compliance
is an important issue.21 The increase in body fat leads to a
rise in the volume of distribution for lipid soluble drugs
and a diminution in the volume of distribution for
hydrophilic drugs. In the cancer population, malnutrition
and hypoalbuminaemia can result in an increased
unbound concentration of drugs that are albumin-bound.22
Hepatic mass and blood flow decrease with age.9,23 The
impact of the decline in hepatic mass and blood flow on
hepatic enzyme function is controversial.24-26
Changes in renal function are less controversial. The
decline in Glomerular Filtration Rate (GFR) with age is
estimated at 0.75 mL/min per year after age 40;
however, approximately one third of patients have no
change in creatinine clearance with age.27 This reduced
renal function does not usually result in increased serum
creatinine levels because of the simultaneous loss of
muscle mass.28 Therefore, serum creatinine is not an
adequate indicator of renal function in the older patient.
All formulas used to calculate renal function have been
primarily validated in a younger group of patients
without renal disease and are not as accurate in older
patients.29,30 The accuracy of the Cockcroft-Gault, Jelliffe
and Wright formulas in a population of older patients
with cancer has been evaluated and the Wright formula
was the most accurate formula to calculate GFR;
however, the majority of patients in this study had a
GFR >50 mL/min.31
The decline in GFR with age translates into
pharmacokinetic alterations of drugs or their active
metabolites which are excreted by the kidneys.
Prudence with adjusting doses of renally excreted drugs
to prevent toxicity cannot be overemphasised.
Polypharmacy, which is common in the elderly,
increases the risk of adverse events.32-34 The older
patient with cancer is particularly at risk for adverse drug
events due to issues relating to polypharmacy. Agents
such as supportive care medications (anticholinergics,
benzodiazepines, dexamethasone) may have exag-
gerated effects in an older person.33,34 In addition,
clearance of chemotherapeutic agents may be affected
by concomitant drugs, which can lead to decreased
clearance of the chemotherapy (placing the patient at
increased risk of toxicity) or increased clearance (placing
the patient at risk of ineffective therapy). 
Many older patients are on common drugs causing
cytochrome P450 related interactions, including selective
serotonin reuptake inhibitors, phenytoin, steroids,
ketoconazole and macrolide antibiotics. These patients
may experience important drug interactions which
involve antineoplastic agents such as ifosfamide, vinca
alkaloids, etoposide, taxanes and aromatase inhibitors.24
Strategies to minimise the risk for drug-to-drug
interactions involve: a thorough medication history
including prescribed medications, over-the-counter
medications and herbal medicines at each visit,
becoming familiar with the lists of drugs that should be
avoided in older patients; eliminating any unnecessary
medications; and paying attention to patient adherence
to prescribed medications.33,35 Moreover, it is essential
to realise that elderly patients often have more than one
clinician prescribing different medications without
adequate communication among them.
Older patients are at increased risk of myelosuppression
and toxicity resulting from age-related decline in organ
function.36 Haematological toxicity is more common in
elderly patients. Chemotherapy is associated with a
higher rate of infection, more hospitalisations and a
higher mortality in older age groups.36 Furthermore, the
increased use of haematopoietic growth factors has led
to a shift in the toxicity profile. The dose-limiting toxicity
of many regimens has shifted to non-haematological
toxicity, particularly neuropathy and gastrointestinal
toxicity, which remain significant problems for older
patients.
It is important to appreciate the limitations of the data
on chemotherapy in the elderly available at present.
Few studies have looked specifically at the older patient
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group, with most analysing a subpopulation of older
participants within larger studies, limiting the numbers,
validity and reliability. Additional studies of
pharmacokinetics of cancer therapies in the older
patient are needed, based on the data to date, it is likely
that more factors in addition to pharmacokinetics and
chronologic age may be significant predictors of
tolerance to chemotherapy. Future pharmacokinetic
studies in older patients should include a thorough
evaluation of physiologic factors, such as baseline renal
function, hepatic function, haemoglobin and albumin
levels. In addition, studies should include an
assessment of factors apart from chronologic age that
independently predict morbidity and mortality in the
geriatric population, including all aspects of functional
status, cognitive state, comorbid illnesses, nutritional
state and psychological status.37-38 Studies that include
these parameters may provide insights into the factors
contributing to tolerability of chemotherapy and lead to
interventions to improve treatment tolerance.
Chemotherapy agents and the data
Although it is beyond the scope of this article, we 
will briefly discuss a few aspects of specific
chemotherapeutic agents commonly used in clinical
practice. In elderly breast cancer patients treated with
doxurubicin and cyclophosphamide there is evidence of
an age-related decrease in absolute neutrophil nadir
count. However, Dees et al concluded that healthy older
patients should not be denied adjuvant chemotherapy
on the basis of age alone.39 There is no reproducible
evidence for systematic dose reduction of
cyclophosphamide based on age alone, particularly in
the adjuvant setting. 
Cisplatin is utilised in the treatment of numerous
malignancies. The clearance is primarily dependent on
renal function. The potential nephrotoxicity of cisplatin is
a concern, but toxicity in the elderly can be minimised
with appropriate safety measures, particularly with
intravenous hydration.40-41 Carboplatin, which has a
mechanism of action similar to cisplatin, is primarily
excreted renally while the remainder binds to tissue
proteins and is inactivated.42 Dosing using creatinine
clearances derived from formulae have limitations,
particularly in elderly patients. Retrospective studies
have attempted to quantify the reliability and the
accuracy of these methods in a particular elderly cancer
patient group.31
Fluoropyrimidines such as fluorouracil and capecitabine
are widely used agents in solid malignancies in the
geriatric population. They are often arbitrarily reduced in
dosage.43-45 The pharmacokinetics of capecitabine for
instance is not affected by age in patients with normal
renal function.46 There is no pharmacokinetic basis for
dose modification based on age alone.47 However, there
may be significant age-related toxicities. An overview of
seven phase III trials involving fluorouracil with either
leucovorin or levamisole showed that no interaction
between age and outcome could be identified.
However, age older than 70 years correlated with a
higher occurrence of treatment-related leucopaenia of
borderline significance.48 A retrospective analysis of
European trials has showed that fit elderly patients
experience equivalent benefits and toxicities as younger
patients.49 
With regard to taxanes, several phase II trials have
concluded that the pharmacokinetic analysis of
differences in age related clearance of this agent were
negligible compared with the interpatient variability in
drug metabolism.50
Conclusions
Optimising cancer care and chemotherapy delivery in
the elderly requires a better understanding of the
specific pharmacokinetic and pharmacodynamic issues
and administration of chemotherapy in this age group.
Utilising a comprehensive geriatric assessment that
incorporates aspects such as polypharmacy, co-
morbidities and social issues will be of great assistance.
Outcomes of such an assessment tool may influence
chemotherapy delivery, toxicity and prognosis. Further
research is required to provide evidence-based models
to guide treatment decisions.
There are great opportunities for research and
development of scientific, evidence-based guidelines
for geriatric oncology practice. There is an increasing
demand for elderly specific cancer research. In an
Australian setting, the development of a geriatric
oncology specific group as a means of facilitating
collaboration with geriatricians, development of specific
elderly research programs and clinical trials, education
and development of treatment guidelines, would further
improve outcomes of our elderly patients undergoing
cancer treatment. 
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